A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Purpose: GI-4000, a series of recombinant yeast expressing four different mutated RAS proteins, was evaluated in subjects with resected ras-mutated pancreas cancer. Methods: Subjects (n = 176) received GI-4000 or placebo plus gemcitabine. Subjects' tumors were genotyped to identify which matche...

Descripción completa

Detalles Bibliográficos
Autores principales: Muscarella, Peter, Bekaii-Saab, Tanios, McIntyre, Kristi, Rosemurgy, Alexander, Ross, Sharona B., Richards, Donald A., Fisher, William E., Flynn, Patrick J., Mattson, Alicia, Coeshott, Claire, Roder, Heinrich, Roder, Joanna, Harrell, Frank E., Cohn, Allen, Rodell, Timothy C., Apelian, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997807/
https://www.ncbi.nlm.nih.gov/pubmed/33786412
http://dx.doi.org/10.1089/pancan.2020.0021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997807/
https://www.ncbi.nlm.nih.gov/pubmed/33786412
http://dx.doi.org/10.1089/pancan.2020.0021

Ejemplares similares